Cyclophosphamide + Thalidomide + Dexamethasone Versus Melphalan + Dexamethasone for the Treatment of Amyloid Light-chain Amyloidosis With Kidney Involvement: A Retrospective Study in Chinese Patients

2019 ◽  
Vol 41 (6) ◽  
pp. 1186-1198 ◽  
Author(s):  
Baojian Liu ◽  
Yan Wang ◽  
Ming Bai ◽  
Di Wang ◽  
Jin Zhao ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Light Chain ◽  
Chinese Patients ◽  
Light Chain Amyloidosis ◽  
Kidney Involvement ◽  
Amyloid Light Chain

scholarly journals A clinicopathological analysis in a large cohort of Chinese patients with renal amyloid light-chain amyloidosis

2012 ◽  
Vol 28 (3) ◽  
pp. 689-697 ◽  
Author(s):  
Ying Yao ◽  
Su-Xia Wang ◽  
You-Kang Zhang ◽  
Zhen Qu ◽  
Gang Liu ◽  
...  
Keyword(s):  
Light Chain ◽  
Large Cohort ◽  
Chinese Patients ◽  
Light Chain Amyloidosis ◽  
Clinicopathological Analysis ◽  
Amyloid Light Chain

The Clinical Characteristics and Prognosis of Chinese Patients With Primary Light-Chain Amyloidosis: A Retrospective Multicenter Analysis

2019 ◽  
Author(s):  
Donghua He ◽  
Fangshu Guan ◽  
Minli Hu ◽  
Gaofeng Zheng ◽  
Pan Hong ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Light Chain ◽  
Clinical Characteristics ◽  
Cardiac Involvement ◽  
Renal Involvement ◽  
Chinese Patients ◽  
Response To Treatment ◽  
Light Chain Amyloidosis ◽  
Hepatic Involvement ◽  
Serum And Urine

Abstract Objective To retrospectively identify the critical characteristics and prognostic factors of primary light-chain amyloidosis. Patients and Methods: Data were collected and compared from 91 patients who were diagnosed with primary light-chain amyloidosis at four hospitals between January 2010 and November 2018. We analyzed the clinical characteristics and performed an overall survival (OS) analysis. Results: Patients (median age, 60 years) were diagnosed with organ involvement of the kidney (91.2%), heart (56%), liver (14.3%), soft tissue (18.7%), or gastrointestinal tract (15.4%), and 68.1% of patients had more than two organs involved. Patients were most commonly treated with bortezomib-based regimens (56%), and only one patient had autologous stem cell transplantation (auto-ASCT). The median OS was 36.33 months and was affected by the ECOG score, renal involvement, cardiac involvement, hepatic involvement and negative immunofixation in the serum and urine after treatment. Multivariate analysis indicated that cardiac involvement and negative immunofixation in the serum and urine after treatment were independent prognostic factors for OS. Conclusion: Cardiac involvement and the hematologic response to treatment were independent prognostic factors for OS in primary light-chain amyloidosis patients. The type and number of organs involved is more important than the number of organs involved for the OS.

scholarly journals Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light‐chain amyloidosis

2020 ◽  
Vol 189 (4) ◽  
pp. 643-649 ◽  
Author(s):  
Oliver C. Cohen ◽  
Faye Sharpley ◽  
Julian D. Gillmore ◽  
Helen J. Lachmann ◽  
Sajitha Sachchithanantham ◽  
...  
Keyword(s):  
Light Chain ◽  
Light Chain Amyloidosis ◽  
Amyloid Light Chain

scholarly journals Prevalence and clinical implications of t(11;14) in patients with amyloid light-chain amyloidosis with or without concurrent multiple myeloma

2019 ◽  
Vol 49 (2) ◽  
pp. 195-198 ◽  
Author(s):  
Hiroki Kobayashi ◽  
Yoshiaki Abe ◽  
Daisuke Miura ◽  
Kentaro Narita ◽  
Akihiro Kitadate ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Light Chain ◽  
Clinical Implications ◽  
Light Chain Amyloidosis ◽  
Amyloid Light Chain

Estimating the Global Epidemiology of Amyloid Light-Chain Amyloidosis With an Incidence-to-Prevalence Model

2019 ◽  
Vol 19 (10) ◽  
pp. e339
Author(s):  
Nicole Zhang ◽  
Dasha Cherepanov ◽  
Dorothy Romanus ◽  
Nishant Kumar ◽  
Michael Hughes ◽  
...  
Keyword(s):  
Light Chain ◽  
Light Chain Amyloidosis ◽  
Global Epidemiology ◽  
Amyloid Light Chain
Sign in / Sign up

Export Citation Format

Share Document